Statement of Principles concerning Creutzfeldt-Jakob disease (Reasonable Hypothesis) (No. 80 of 2022)

The central concept is "reasonable hypothesis". This is a legal standard of proof used in veterans' compensation. It is lower than the civil standard of balance of probabilities, but it requires more than a mere possibility. The instrument sets out a list of factors that, if satisfied, are deemed sufficient to raise a reasonable hypothesis connecting CJD to service. The factors are not exhaustive in the sense that other evidence might also raise a hypothesis, but the instrument provides a safe harbour: if a factor is present and related to service, the decision-maker must accept the hypothesis.

The instrument defines "Creutzfeldt-Jakob disease" precisely, meaning a spongiform encephalopathy with abnormal prion protein accumulation. This excludes other prion diseases such as fatal familial insomnia or Gerstmann-Straussler-Scheinker syndrome unless they meet the definition. The instrument distinguishes between sporadic (classical) CJD and variant CJD. Variant CJD is separately defined as a form with younger onset, protracted course, sensory disturbances, psychiatric symptoms, and florid amyloid plaques. This distinction matters because the factors for variant CJD are more specific: receiving blood or blood products from an infected person, consuming beef or beef products from a country with bovine spongiform encephalopathy (BSE) infection in cattle, or having percutaneous exposure to blood or tissue from an animal infected with BSE. These factors apply only to variant CJD, not to sporadic CJD.

Another key concept is "human tissue or product as specified". This is a closed list: corneal transplant, liver transplant, albumin infusion, cadaveric human pituitary hormones, or human dura mater as a graft or in radiographic embolisation procedures. This is narrower than any human tissue product generally. The factor requires receipt of specified treatment at least six months before the clinical onset of CJD. This incubation period reflects the known latency of prion diseases from iatrogenic sources.

"Major surgery that requires general, spinal or epidural anaesthesia" is another factor with a six-month latency. The instrument gives examples including neurosurgery, obstetric, gynaecological, or gastrointestinal surgical procedures, and explicitly excludes minor surgery such as needle aspiration, biopsy, superficial incision, or endoscopy. This factor is not limited to variant CJD; it applies to any CJD, covering surgical transmission of prions.

For variant CJD only, there are three factors: receiving blood or blood products from a person infected with variant CJD, consuming beef or beef product from an area or country with evidence of BSE infection in cattle at the time of consumption, or percutaneous exposure to blood or tissue from an animal infected with BSE. Each of these factors has a latency of at least three years before clinical onset. The instrument notes that consumption of contaminated beef can occur in countries that have imported beef from a BSE-affected country, even if the consuming country has no domestic BSE.

"Relevant service" is defined in the dictionary and includes operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, and warlike or non-warlike service under the MRCA. This defines the scope of persons who can rely on the instrument.

"Terminal event" is defined as the proximate or ultimate cause of death, listing pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function. This ensures that death contributed to by CJD is covered even if CJD is not the immediate cause of death.

The instrument also has a cross-reference mechanism: if a factor refers to an injury or disease covered by another Statement of Principles, then the factors in that other SoP apply as in force from time to time. This means that if a claimant has, for example, undergone major surgery (factor (2)), and that surgery involved a condition covered by another SoP (e.g., a head injury requiring neurosurgery), the claimant may need to also satisfy the factors of that other SoP to link the surgery to service. This is a cascading evidentiary requirement.

This instrument directly affects veterans, members of the Peacekeeping Forces, members of the Forces under the VEA, and members of the Australian Defence Force under the MRCA who have claimed or may claim compensation for Creutzfeldt-Jakob disease. It also affects their dependants and legal representatives who might claim on their behalf after death. The instrument is gender-neutral but likely applies predominantly to older veterans given the age distribution of sporadic CJD and the historical exposure of military personnel to certain risks (e.g., surgical procedures, blood transfusions, deployments to BSE-affected regions).

Indirectly, the instrument affects decision-makers in the Department of Veterans' Affairs (DVA) and the Military Rehabilitation and Compensation Commission, as well as medical professionals who provide evidence in support of claims. The instrument reduces the amount of medical judgement required by prescribing specific factors; if a factor is established and related to service, the claim must be accepted for the purposes of the reasonable hypothesis stage. This creates predictability for claimants but also rigidity: a claimant who cannot fit within any factor may have difficulty raising a reasonable hypothesis, even if there is plausible but novel evidence.

The instrument also affects the Australian public as taxpayers, because accepted claims have costs in the form of ongoing compensation payments, medical treatment, and other entitlements. The number of claims likely to succeed is small given the rarity of CJD (about one per million per year), but the cost per case can be high due to the progressive and fatal nature of the disease.

The instrument may also affect private medical practitioners and hospitals when they are asked to provide evidence about treatment histories. The "human tissue or product as specified" factor requires proof of receipt of specific treatments, which may be difficult to document decades later. The major surgery factor requires evidence of the type of anaesthesia and the nature of the procedure, which may be recorded in medical records but not always easily retrievable.

For variant CJD, geographical factors become relevant. Persons who served in the United Kingdom during the 1980s and 1990s BSE outbreak, or who consumed beef products there during that period, could potentially meet the factor (3)(b). This affects veterans who served in the UK or in other countries that imported BSE-contaminated beef. The instrument does not require proof that the specific beef consumed was contaminated, only that the area or country had evidence of BSE infection in cattle at the time. This reduces the claimant's evidentiary burden but also creates a potential for large numbers of claims from veterans who served in BSE-affected regions, even if their individual risk was very low.

The instrument explicitly applies to claims under section 120A of the VEA and section 338 of the MRCA. These provisions govern claims for operational, peacekeeping, hazardous, British nuclear test defence, warlike, and non-warlike service. This means that a peacetime member who has non-operational service only may have a higher standard of proof (balance of probabilities) under other provisions, and this instrument may not apply to them unless the claim falls under the specified sections. So the instrument does not cover all members of the ADF uniformly.

The instrument itself imposes no duties on private individuals. It creates a right for a claimant to have a reasonable hypothesis recognised if they can establish one of the factors and show it is related to service. The duty falls on the decision-maker to accept the hypothesis if those conditions are met. The instrument does not create a duty for medical practitioners to report or test for CJD; that is a matter of clinical practice.

The most important right is the right of the claimant to rely on the instrument as a safe harbour. If the claimant presents evidence that they received a specified human tissue product at least six months before onset, then the decision-maker must treat that as sufficient for the reasonable hypothesis. The claimant does not need to prove the precise mechanism of prion transmission beyond establishing the factor.

The decision-maker has a duty to apply the instrument correctly. If the decision-maker rejects a claim because the factor is not present, they must give reasons. The instrument is binding; it is not a guideline. The decision-maker may not substitute their own medical opinion for the factors set by the Repatriation Medical Authority. However, if the claimant presents evidence that does not match a factor but still argues a reasonable hypothesis, the decision-maker must still consider that evidence on its merits, because the instrument does not say that the factors are exclusive.

The instrument also imposes a duty on the claimant to produce evidence of the factor. The burden of proof is on the claimant to satisfy the reasonable hypothesis standard. For the factors that require a time relationship (at least six months or at least three years before clinical onset), the claimant must provide medical evidence of the date of clinical onset of CJD and the date of the alleged exposure. CJD diagnosis is difficult and often made post-mortem; clinical onset can be hard to pinpoint. This creates a practical burden.

There is a right for dependants. If a person dies from CJD and the death is contributed to by the disease, the dependants may claim benefits. The instrument defines death to include terminal events contributed to by CJD, so even if the immediate cause of death is pneumonia, the claim can succeed if CJD contributed.

The instrument also incorporates other Statements of Principles by reference. This imposes a duty on the claimant to also satisfy the factors of those other SoPs if the factor in this SoP refers to an injury or disease covered by another SoP. For example, if a claimant relies on the factor of "major surgery", and that surgery was for a condition like malignant neoplasm that is covered by a separate SoP for cancer, then the claimant must also show that the cancer (and its surgical treatment) is related to service under its own SoP. This is a layering of evidentiary requirements that can be complex.

This instrument is not a penal statute. It does not create offences or prescribe fines. Enforcement is through the administrative claims process. If a decision-maker fails to apply the instrument correctly, the claimant may seek review by the Veterans' Review Board, the Administrative Appeals Tribunal, or the Federal Court (on questions of law). There are no criminal penalties for misstatement by a claimant, but the general law of fraud and false statements in claims for Commonwealth benefits applies. The instrument itself is silent on penalties.

The Repatriation Medical Authority has power to make and revoke such instruments. Non-compliance with the instrument by a decision-maker could lead to a successful challenge by the claimant. The instrument is a legislative instrument subject to disallowance by Parliament, but that is a political check, not a legal penalty.

In terms of enforcement against veterans or members, there is none. A claimant who does not establish a factor simply fails the claim. There is no penalty for making a claim that does not meet the factors, other than the time and cost of an unsuccessful claim.

The instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986. That section gives the Repatriation Medical Authority power to determine Statements of Principles about injuries or diseases. So the primary interaction is with the VEA and the MRCA. The instrument specifically applies to claims under section 120A of the VEA and section 338 of the MRCA. Those sections set the standard of proof: for operational service and similar, the standard is reasonable hypothesis (for the nexus between disease and service). The instrument tells the decision-maker what evidence is sufficient to raise that hypothesis.

The instrument also interacts with other Statements of Principles through section 11. If a factor in this SoP refers to an injury or disease covered by another SoP, that other SoP applies as in force from time to time. This creates a network of instruments. For example, a person who underwent major surgery might also need to satisfy the SoP for the condition that necessitated the surgery, if that condition is itself a disease or injury covered by a SoP. This can create cascading evidentiary chains.

The instrument does not override medical privacy laws or record-keeping obligations. However, obtaining the necessary evidence may require access to medical records, which is governed by state and federal health privacy legislation. That is an external interaction.

The instrument also interacts with the ICD-10-AM coding system, but it expressly provides that the meaning of CJD for the SoP is the one in subsection 7(2), not merely the ICD code. So a person with a diagnosis code of A81.0 (other slow virus infections of central nervous system) may not necessarily be covered if the clinical definition is not met. This protects against misclassification.

The instrument does not interact with criminal law, workers' compensation laws, or tort law. It is specific to the military compensation system.

This instrument (No. 80 of 2022) repeals and replaces the Statement of Principles concerning Creutzfeldt-Jakob disease No. 76 of 2014 (Federal Register of Legislation No. F2014L01138). The instrument provides the date of repeal in section 4. The 2014 instrument was itself a replacement for earlier instruments. The instrument does not explain the reasons for the changes, but a comparison of the 2022 version with the 2014 version would likely show updated factors reflecting new medical-scientific evidence. The instrument commences on 19 September 2022. There is no mention of transitional provisions, so claims made after that date are subject to the new factors. Claims made before that date would be governed by the 2014 instrument.

The Repatriation Medical Authority reviews and updates Statements of Principles periodically as medical knowledge evolves. There is no publicly available official reasons document for this specific amendment, but the authority typically publishes explanatory statements. However, the user has not provided that, so we rely only on the instrument itself. The instrument is the current version as of its date.

The instrument itself does not reference any litigation. Statements of Principles have been the subject of extensive litigation in the Federal Court and the High Court of Australia, particularly regarding the standard of review, the meaning of "reasonable hypothesis", and the scope of the Repatriation Medical Authority's powers. Key cases include Repatriation Commission v Bey (1997) 79 FCR 364 and Repatriation Commission v Gorton (2001) 110 FCR 321. However, those cases do not specifically concern CJD. There is no publicly known litigation specifically concerning the CJD SoP No. 80 of 2022 as of the date of this analysis. Given the rarity of CJD, litigation is likely minimal. However, the instrument could be challenged if a claimant argues that the factors are too restrictive or not based on sound medical-scientific evidence. As this is a new instrument, no litigation history exists so far.

One gotcha is the narrow definition of "human tissue or product as specified". It is a closed list. A claimant who received a blood transfusion (which is not listed) that was later found to be from a CJD-infected donor cannot rely on factor (1) unless the blood product is specifically a blood product as defined for variant CJD. But the transfusion factor for variant CJD is in factor (3)(a), which requires the donor to be infected with variant CJD, not sporadic CJD. So a transfusion from a donor with sporadic CJD is not covered by any factor. This gap could be significant because iatrogenic transmission of sporadic CJD through blood transfusion is theoretically possible but not recognised in the instrument.

Another gotcha is the temporal requirement. For iatrogenic factors (human tissue product, major surgery), the exposure must be at least six months before clinical onset. For variant CJD factors, the latency is at least three years. If the exposure occurred after clinical onset (which is impossible) or too close to onset, the factor is not met. Clinical onset of CJD can be subtle and may have occurred before the claimant or their doctors realise. The date of diagnosis may be well after actual onset. The instrument does not define "clinical onset". This can be contested.

The major surgery factor excludes needle aspiration, biopsy, superficial incision, endoscopy. A claimant who had a brain biopsy to diagnose CJD cannot rely on that as the factor, because that is a biopsy excluded. But the factor requires surgery at least six months before onset; brain biopsy after onset would be irrelevant anyway.

For variant CJD factor (3)(b), the requirement is consuming beef or beef product from an area or country with evidence of BSE infection in cattle at the time of consumption. The claimant need not prove that the specific beef was contaminated, only that the area had BSE. However, the claimant must still prove they consumed beef from that area. This might be difficult if they consumed unknown sources. The instrument also notes that imported beef from BSE countries can be a source. This expands the potential exposure to many veterans who ate beef in Australia that was imported from the UK during the BSE epidemic. But the claimant must show evidence of the origin of the beef, which is often impossible.

The cross-referencing in section 11 is a trap. If the major surgery factor applies, and the surgery was for a disease that has its own SoP, the claimant must also satisfy that SoP. This means the claimant may need to prove two separate chains: that the underlying disease is related to service, and that the surgery for it led to CJD. This can be very burdensome.

The instrument does not address genetic forms of CJD. Familial CJD is inherited due to prion protein gene mutations. The factors in section 9 all relate to acquired (iatrogenic or dietary) causes. A person with familial CJD likely cannot raise a reasonable hypothesis under this instrument, unless they also have an acquired factor. But the instrument's definition of CJD does not exclude familial forms; it only requires spongiform encephalopathy with abnormal prion protein. So a person with familial CJD could claim, but they would need to establish one of the factors, which may be impossible. This could lead to denial of claims for familial CJD even if the disease is genuinely linked to service through stress or other mechanisms not in the instrument. The decision-maker might argue that the reasonable hypothesis requires a factor from the SoP, and if none exist, the claim fails.

Finally, the concept of "relevant service" is limited to the services listed in the dictionary. This excludes members who served in other capacities, such as continuous full-time service that is not operational or warlike. A reservist on non-operational service may not qualify under the MRCA if the service is not warlike or non-warlike? The definition seems broad but may exclude peacetime home service that is not classified as hazardous or operational. Claimants must check the specific service type.

This instrument is not a compliance document for the general public; it is a decision-making tool for claims processors and a guide for veterans' advocates. For a claimant to comply and succeed, they should:

1. Obtain a confirmed diagnosis of Creutzfeldt-Jakob disease that meets the definition in subsection 7(2). This typically requires neuropathological confirmation or clinical syndrome with MRI, EEG, and CSF analysis. The diagnosis should specify whether it is sporadic or variant CJD.

2. Determine the date of clinical onset. This may be contested; a neurologist should provide an opinion. The onset is when symptoms first appear, not when diagnosed.

3. Review the factors in section 9. Identify which factor(s) may apply. For sporadic CJD, only factors (1) and (2) are possible (receiving specified human tissue product or major surgery at least six months prior). For variant CJD, additionally consider factors (3)(a)-(c) with three-year latency.

4. Gather medical records to prove the exposure. For factor (1), records of corneal transplant, liver transplant, albumin infusion, receipt of cadaveric human pituitary hormones, or human dura mater graft or embolisation. These are rare procedures often documented in hospital records. Check if the records show timing at least six months before symptom onset.

5. For factor (2), obtain records of major surgery requiring general, spinal or epidural anaesthesia. The surgery must be at least six months before onset. Obtain anaesthesia records and operation notes.

6. For variant CJD factors: (a) document blood transfusion records showing the donor was infected with variant CJD; (b) document consumption of beef or beef product from a country with BSE at the time, and the timing of consumption at least three years before onset. This may require travel records, rations lists, or evidence of posting to the UK, France, or other BSE-affected countries. (c) document percutaneous exposure (needlestick, wound) to blood or tissue from a BSE-infected animal. This would apply mostly to veterinarians or abattoir workers, less likely to military members.

7. Ensure that the exposure itself is related to the person's relevant service. For example, if surgery was performed at a military hospital, that is likely service-related. If a member consumed beef while on deployment to the UK, that could be service-related.

8. If a factor refers to another SoP (e.g., the major surgery was for a condition that has its own SoP), then also gather evidence to satisfy that SoP. This may require separate legal work.

9. Submit a claim under the VEA or MRCA with supporting medical and service documents. The decision-maker will apply the SoP. If the claim is denied, seek review. The claimant should ensure they explicitly reference the relevant factor and the evidence linking it to service.

10. Work with an advocate or lawyer experienced in military compensation claims. The instrument is technical, and the evidence requirements are strict.

For decision-makers, compliance means correctly identifying which factors apply and ensuring they do not accept a factor that is not supported by evidence or that lacks the required temporal relationship. They must also apply the cross-referencing to other SoPs.

Overall, compliance requires meticulous record-keeping, expert medical opinion, and careful legal analysis of service history. Given the rarity of CJD, few practitioners will be familiar with this instrument, making specialised advice essential.